Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy. ZUMA-3 is a single-arm Phase 1/2 study in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The results provide guidance on dosing and safety management for KTE-X19 to inform the ongoing Phase 2 study. The data were presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 – June 4 (Abstract #7006).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190601005017/en/
By the end of Phase 1, 45 patients received KTE-X19 at one of three different doses levels [2 x 106 cells/kg (n=6), 1 x 106 cells/kg (n=23), or 0.5 x 106 cells/kg (n=16)]. Patients enrolled in this study were primary refractory or relapsed/refractory after at least two prior lines of therapy. Of 41 patients who were evaluable for efficacy after a minimum two months of follow-up (median follow-up of 16 months), 68 percent achieved complete response (CR) or CR with incomplete hematological recovery (CRi) and 100 percent of responders had undetectable minimal residual disease (MRD). Of the 23 patients treated with the dose level that will be used in the ongoing Phase 2 study (1 x 106 cells/kg), 19 were evaluable for efficacy. At the time of data cut-off (median duration of remission = 12.9 months), 16 (84 percent) patients achieved CR or CRi, and 12 patients (75 percent) were in ongoing response.
No dose-limiting toxicities (DLTs) were identified. Grade ≥3 cytokine release syndrome (CRS) events and neurologic events occurred in 29 percent and 38 percent of all patients, respectively. As previously reported, two patients experienced KTE-X19–related Grade 5 adverse events (AEs) during the study; one developed stroke in the context of CRS and neurologic events, and one experienced multiorgan failure secondary to CRS. Among patients receiving 1 x 106 cell/kg (n=23), 26 percent experienced Grade ≥3 CRS, and 43 percent experienced Grade ≥3 neurologic events.
A revised AE management protocol was implemented in nine patients treated with 1 x106 cells/kg of KTE-X19 during the study. In this revised protocol, corticosteroids were initiated at onset of Grade ≥2 neurologic events (versus previous onset of Grade 3) and tocilizumab was only given for management of toxicities in the context of CRS (versus prophylactic administration in Cohort 2). Of those patients, two (22 percent) had Grade 3 CRS and one (11 percent) had Grade 3 neurologic events. There were no Grade 4/5 events.
“Adults with relapsed or refractory ALL represent an extremely difficult-to-treat patient population,” said Bijal Shah, MD, ZUMA-3 investigator and medical oncologist, Moffitt Cancer Center, Tampa, Florida. “We’re encouraged by the high response rates in this study, as well as the reduced incidence and severity of CRS and neurologic events that were observed following implementation of the revised safety management protocol. We are now evaluating the use of KTE-X19 at the selected dose with this safety management protocol in the ongoing ZUMA-3 Phase 2 study.”
“The completion of the Phase 1 portion of the ZUMA-3 trial is an important milestone for our second investigational CAR T cell therapy,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead. “We are pleased with the high response rates observed with KTE-X19 in this trial, and the progress of our broader effort aimed to further improve the benefit/risk profile of CAR T therapy through the investigation of novel safety management approaches.”
This abstract has also been selected to be included in the 2019 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
KTE-X19 is an investigational therapy that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for any uses. Efficacy and safety have not been established.
ALL is an aggressive type of blood cancer which can also involve the lymph nodes, spleen, liver, central nervous system and other organs.
ZUMA-3 is an ongoing multicenter, registrational Phase 1/2 study in adult patients (≥18 years old) with ALL whose disease is refractory to or has relapsed following standard chemotherapy or hematopoietic stem cell transplantation. The objectives of the study are to evaluate the safety and efficacy of KTE-X19 in this patient population.
KTE-X19 is an investigational CD19 CAR T cell therapy. KTE-X19 has the same construct as axicabtagene ciloleucel; however, the manufacturing process for KTE-X19 differs from that of axicabtagene ciloleucel and includes the enrichment of lymphocytes. Lymphocyte enrichment is necessary in certain B-cell malignancies for which KTE-X19 in under investigation. KTE-X19 is currently in Phase 1/2 trials in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Kite’s ability to complete Phase 2 of the ZUMA-3 study of KTE-X19 in adult patients with relapsed or refractory acute lymphoblastic leukemia in the currently anticipated timelines, or at all. In addition, there is the possibility of unfavorable results from other ongoing and additional clinical trials involving KTE-X19. Further, Kite may be unable to obtain regulatory approval for KTE-X19 from the FDA or other regulatory authorities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.
For more information on Kite, please visit the company’s website at www.kitepharma.com . Learn more about Gilead at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-300
Sung Lee, Investors
Nathan Kaiser, Media
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
MYbank Works With Financial Institution Partners to Serve Over 15 Million SMEs24.6.2019 05:42:00 CEST | Pressemelding
MYbank, a leading online private commercial bank in China with a focus on SME financing, today announced that the bank’s Star Plan has enabled MYbank, with its financial institution partners, to serve over 15 million small and micro enterprises (SMEs). SMEs are key drivers of economic growth and this partnership is now serving more SMEs than any other in the world. The announcement comes on the day that MYbank celebrates its 4th Anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190623005055/en/ MYbank’s 310 lending model enables inclusive finance for SMEs in China (Photo: Business Wire) MYbank’s Star Plan was announced on June 21, 2018 with the aim of using technology to enable 1,000 financial institution partners to provide more cost-effective financing services to 30 million SMEs in China within a three-year period. A little over a year later and the Star Plan is showing significant progress. As of June 2019, lev
CORRECTING and REPLACING Cooper & Turner Announces Exclusivity for Potential Combination with Beck Industries21.6.2019 19:51:00 CEST | Pressemelding
Please replace the release dated June 19, 2019, with the following corrected version due to changes to the headline and first sentence of release. The corrected release reads: COOPER & TURNER ANNOUNCES EXCLUSIVITY FOR POTENTIAL COMBINATION WITH BECK INDUSTRIES Andaray (Holdings) Limited and its direct and indirect subsidiaries (“Cooper & Turner”) have entered into an exclusivity agreement with Beck Industries (“Beck”) for potential combination of the two groups. The contemplated combined entity aims to be the first truly global manufacturer of safety critical fasteners, together supporting a broader range of industries – including renewable energy, tunneling, construction, rail, heavy equipment, downstream oil & gas, power generation and nuclear, among others. Headquartered in Sheffield, England, Cooper & Turner serves a global customer base with manufacturing and distribution operations across the European Union, China and North America. This worldwide network enables Cooper & Turner
Aqua Comms Expands Presence to Interxion’s Copenhagen Campus21.6.2019 08:00:00 CEST | Pressemelding
INTERXION HOLDING NV (NYSE: INXN), a leading European provider of carrier and cloud-neutral colocation data centre services, today announced that it has signed an agreement with Aqua Comms, the operator of subsea fibre-optic networks interconnecting the United States and Europe, enabling interconnection to the America Europe Connect-2 (AEC-2) subsea cable system from Interxion’s data centre in Copenhagen. AEC-2 is Aqua Comms’s portion of the Havfrue subsea cable project, connecting New Jersey, U.S.A., to Ireland, and Denmark. The America Europe Connect-2 cable is scheduled to land in Blaabjerg, near Esbjerg in September 2019 and will be the first new cable connecting Denmark to the U.S. in nearly two decades. Aqua Comms supplies fibre pairs, spectrum and capacity networking solutions to the global media, content and carrier markets. “The large number of networks and content platforms present at Interxion’s Copenhagen campus makes it an efficient location for AEC-2 to interconnect with
Maor raises close to 100M$ for its first fund MAOR 121.6.2019 08:00:00 CEST | Pressemelding
Maor GP, a Luxembourg based co-investment fund dedicated to Israeli-related technology, is proud to announce the final closing of its first fund, Maor 1, at its target close to 100M$. Maor 1 is the first Luxembourg-based Israeli tech fund created to facilitate access of European investors and in particular European Family offices to the Israeli Technology ecosystem and opportunities. Rothschild & Co is a cornerstone investor in the fund comprising mainly European Family offices. Maor is a Hebrew name and our free translation of it is Explorer. Maor’s mission is to explore and invest in the leading technology ecosystem of Israel while bridging the gap between Europe and Israel. With a very strong local team in Israel and a very strong corporate network in Europe, Maor can directly source the best Israeli startups and help them grow in Europe, find partners, clients or acquisition targets and eventually create value for our investors. We, at Maor thank all our Limited Partners for their
digital.security Introduces the First European Security Label for Connected Solutions21.6.2019 07:00:00 CEST | Pressemelding
digital.security, the leading European certifier for connected object security, has just announced the launch of the IoT Qualified as Secured (IQS) programme – the first certification programme for Internet of Things (IoT) designers who want to have the security of their IoT solutions checked by an independent third party. Designed for users, this label can be used by IoT designers to check the security of systems that use connected objects. It serves as a reliable and independent indicator for future adopters or users, whether they are professionals or private individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190621005018/en/ The programme featuring the IQS pictogram, IoT manufacturers can check the security of their systems that use connected objects. The IQS label can be awarded to companies in all economic sectors for a period of 2 years and is based on a reference framework made up of national and internationa
INDX Releases 2019 Passive Income Report, Expands Into Staking and DPoS21.6.2019 06:00:00 CEST | Pressemelding
INDX, a London-based crypto passive income fund, has released a report comparing traditional assets with their cryptocurrency counterparts that generate a regular payout. Read the report for free here. The firm has also expanded the scope of its native INDX token, which currently pays a quarterly dividend, by adding two additional revenue generating asset classes: Delegated Proof of Stake (DPoS) and Staking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190620005725/en/ The INDX report, entitled ‘Traditional vs Crypto Passive Income’, compares the performance of government bonds, tracker funds, and peer-to-peer lending, with the emerging generation of crypto assets: Staking, Masternodes and DPoS. The report finds the financial barriers common among traditional income investments are replaced by more technical ones, as more adventurous investors seek to add them to their crypto portfolios. While presenting greater risk, the